Please assess the completion status of the following clinical trial:

Trial Title: Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Maintenance hemodialysis therapy for end-stage renal disease~2. Age 18-85 years~3. ≥3 calendar months since dialysis initiation. Note if a patient has been on dialysis for ≥3 but less than 6 calendar months, there must be no hospitalizations during the 6 weeks prior to screening, and no change in estimated dry weight (EDW) within 2 weeks of the screening date.~4. For women of childbearing potential, willingness to use a highly effective method of birth control for up to 4 weeks after the last dose to study drug.~5. Ability to provide informed consent~Exclusion Criteria:~1. Serum potassium ≥6.5 mEq/L within the 3 months prior to screening~2. Serum potassium level ≥6.0 mEq/L within 2 weeks prior to the baseline visit. If a potassium value is not available through routine clinical care during this 2-week period a potassium measurement will be performed as a research test.~3. Unscheduled dialysis for hyperkalemia within the 3 months prior to screening~4. Pre-dialysis systolic blood pressure \<100 mm Hg within 2 weeks prior to screening or at the baseline visit~5. 2 or more dialysis sessions within the month prior to screening with either 2 intra-dialytic measurements of systolic blood pressure \<80 mm Hg or muscle cramping, light-headedness, nausea or hypotension requiring infusion of saline or other intervention directed at hypotension~6. Current dual use of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)~7. Current use of digoxin~8. Current use of spironolactone or eplerenone~9. Allergy to spironolactone~10. Inability to maintain dialysis machine blood flow ≥300 mL/min during any of the most recent 3 dialysis sessions prior to the screening visit as an indicator of vascular access dysfunction~11. Mitral valve repair or replacement~12. Severe mitral valve disease by echocardiography, coronary angiography or cardiac magnetic resonance imaging~13. Anticipated kidney transplant, change to peritoneal dialysis, or transfer to another dialysis unit within 9 months~14. Expected survival \<9 months~15. Pregnancy, anticipated pregnancy, or breastfeeding~16. Incarceration~17. Participation in another intervention study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone 12.5 mg (Type: ACTIVE_COMPARATOR): Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
- Spironolactone 25 mg (Type: ACTIVE_COMPARATOR): Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
- Spironolactone 50 mg (Type: ACTIVE_COMPARATOR): Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be treated with placebo for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete